Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation

被引：7

作者：

Chen, Runzhe ^{[1
]}

Campbell, Jos L. ^{[2
,3
]}

Chen, Baoan ^{[1
]}

机构：

[1] Southeast Univ, Dept Hematol & Oncol, Zhongda Hosp, Key Dept Jiangsu Med,Med Sch, Nanjing 210009, Jiangsu, Peoples R China

[2] Stanford Univ, Dept Radiol, Mol Imaging Program Stanford, Palo Alto, CA 94304 USA

[3] RMIT Univ, Sch Appl Sci, Melbourne, Vic, Australia

来源：

ONCOTARGETS AND THERAPY | 2015年 / 8卷

关键词：

acute lymphoblastic leukemia; relapse; allogeneic hematopoietic stem cell transplantation; prevention; therapy; MINIMAL RESIDUAL DISEASE; VERSUS-HOST-DISEASE; DONOR LYMPHOCYTE INFUSION; BONE-MARROW-TRANSPLANTATION; ADULT PATIENTS; HIGH-RISK; PEDIATRIC-PATIENTS; UNRELATED DONORS; CHILDHOOD; CHILDREN;

D O I：

10.2147/OTT.S78567

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Relapse of acute lymphoblastic leukemia remains a major cause of death in patients following allogeneic hematopoietic stem cell transplantation. Several factors may affect the concurrence and outcome of relapse, which include graft-versus-host disease, minimal residual disease or intrinsic factors of the disease, and transplantation characteristics. The mainstay of relapse prevention and treatment is donor leukocyte infusions, targeted therapies, second transplantation, and other novel therapies. In this review, we mainly focus on addressing the impact of graft-versus-host disease on relapse and the prophylaxis and treatment of acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. We also make recommendations for critical strategies to prevent relapse after transplantation and challenges that must be addressed to ensure success.

引用

页码：405 / 412

页数：8

共 80 条

[1] Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission [J].

Afify, Z ;

Hunt, L ;

Green, A ;

Guttridge, M ;

Cornish, J ;

Oakhill, A .

BONE MARROW TRANSPLANTATION, 2005, 35 (11) :1041-1047

[2] Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts [J].

Agnusdei, V. ;

Minuzzo, S. ;

Frasson, C. ;

Grassi, A. ;

Axelrod, F. ;

Satyal, S. ;

Gurney, A. ;

Hoey, T. ;

Seganfreddo, E. ;

Basso, G. ;

Valtorta, S. ;

Moresco, R. M. ;

Amadori, A. ;

Indraccolo, S. .

LEUKEMIA, 2014, 28 (02) :278-288

[3] NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies [J].

Alyea, Edwin P. ;

DeAngelo, Daniel J. ;

Moldrem, Jeffrey ;

Pagel, John M. ;

Przepiorka, Donna ;

Sadelin, Michel ;

Young, James W. ;

Giralt, Sergio ;

Bishop, Michael ;

Riddell, Stan .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) :1037-1069

[4]

Appelbaum FR, 2014, BIOL BLOOD MARROW TR, V20, P1040

[5] Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience [J].

Arellano, Martha L. ;

Langston, Amelia ;

Winton, Elliott ;

Flowers, Christopher R. ;

Waller, Edinind K. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) :116-123

[6] Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? [J].

Balduzzi, Adriana ;

Di Maio, Lucia ;

Silvestri, Daniela ;

Songia, Simona ;

Bonanomi, Sonia ;

Rovelli, Attilio ;

Conter, Valentino ;

Biondi, Andrea ;

Cazzaniga, Giovanni ;

Valsecchi, Maria G. .

BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (03) :396-408

[7] The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse [J].

Bandapalli, Obul R. ;

Schuessele, Stephanie ;

Kunz, Joachim B. ;

Rausch, Tobias ;

Stutz, Adrian M. ;

Tal, Noa ;

Geron, Ifat ;

Gershman, Nava ;

Izraeli, Shai ;

Eilers, Juliane ;

Vaezipour, Nina ;

Kirschner-Schwabe, Renate ;

Hof, Jana ;

von Stackelberg, Arend ;

Schrappe, Martin ;

Stanulla, Martin ;

Zimmermann, Martin ;

Koehler, Rolf ;

Avigad, Smadar ;

Handgretinger, Rupert ;

Frismantas, Viktoras ;

Bourquin, Jean Pierre ;

Bornhauser, Beat ;

Korbel, Jan O. ;

Muckenthaler, Martina U. ;

Kulozik, Andreas E. .

HAEMATOLOGICA, 2014, 99 (10) :E188-E192

[8]

Bar Merav, 2014, Leuk Res Treatment, V2014, P421723, DOI 10.1155/2014/421723

[9] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[10] Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation [J].

Bastos-Oreiro, Mariana ;

Perez-Corral, Ana ;

Martinez-Laperche, Carolina ;

Bento, Leyre ;

Pascual, Cristina ;

Kwon, Mi ;

Balsalobre, Pascual ;

Munoz, Cristina ;

Buces, Elena ;

Serrano, David ;

Gayoso, Jorge ;

Buno, Ismael ;

Anguita, Javier ;

Luis Diez-Martin, Jose .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (03) :239-246

← 1 2 3 4 5 6 7 8 →